HORIZON FLEXIBLE INCOME ETF (FLXN) Stock Overview

Can you describe the business of HORIZON FLEXIBLE INCOME ETF?

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. The company is headquartered in Burlington, Massachusetts and currently employs 257 full-time employees. The company went IPO on 2014-02-12. The firm is focused on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), the common form of arthritis. Its product candidate, ZILRETTA, is the intra-articular (IA) injection indicated for the management of OA knee pain. The company is approved by Food and Drug Administration (FDA) to manage osteoarthritis knee pain. The ZILRETTA is a non-opioid therapy that employs its microsphere technology to provide pain relief. The company markets ZILRETTA to prescribing physicians through its own field sales force of Musculoskeletal Business Managers (MBMs). The firm's other product candidates include FX201 and FX301. The FX201 is an IA gene therapy product candidate in clinical development for the treatment of OA. The FX301 is developed as a locally administered peripheral analgesic nerve block for management of post-operative pain.

What is the stock price of HORIZON FLEXIBLE INCOME ETF today?

The current stock price of FLXN is 25.76 USD. The price increased by 0.29% in the last trading session.

What is the ChartMill technical and fundamental rating of FLXN stock?

FLXN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 0 out of 10.

Would investing in HORIZON FLEXIBLE INCOME ETF be a good decision?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on FLXN.